NCT04551768View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

August 17, 2021

Study Completion Date

August 17, 2021

Conditions
COVID19
Interventions
DRUG

50 mg/mL Virazole

50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.

DRUG

100 mg/mL Virazole

100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.

Trial Locations (4)

10676

Bausch Health Site 201, Athens

11527

Bausch Health Site 203, Athens

22320

Bausch Site 304, Tijuana

68100

Bausch Health Site 204, Alexandroupoli

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT04551768 - Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 | Biotech Hunter | Biotech Hunter